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51 PRECLINICAL ANIMAL MODELS IN SINGLE SITE CARTILAGE
DEFECT TESTING: A SYSTEMATIC REVIEW
B.J. Ahern1, J. Parvizi2, R. Boston1, T.P. Schaer1. 1University of
Pennsylvania School of Veterinary Medicine, Kennett Square, PA, USA,
2Rothman Institute, Philadelphia, PA, USA
Purpose: The goal of translational research is to transform biologic
knowledge into new treatments for human disease. Although preclinical
models replicate some of the features of naturally occurring disease, they
invariably fail to reproduce the complexity of the degenerative disorder,
and by their experimental nature, they are readily manipulated to maxi-
mize evidence of efﬁcacy. The result is that successful translation from
preclinical models to clinically effective therapy is uncommon, and that
clinical trials are often undertaken without a comprehensive and realistic
preclinical portfolio of studies to optimize their design. This review is an
attempt to evaluate preclinical studies in the literature using criteria more
reﬂective of the human clinical picture in single site joint resurfacing.
Methods: A systematic review was conducted from 1990 to 2007. Only
studies with single site defects using the stiﬂe joints were included.
The following variables were tabulated and analyzed: species, age,
animal number and defect dimensions. For all animal studies and six
large representative human studies the total defect volume and chon-
dral/subchondral components were calculated and subsequently com-
pared using cluster analysis. This method of evaluation allowed species
to be objectively assembled into sub-strata comprising ‘groups’ of ‘sim-
ilar’ species. The suitability of each species used for single site defect
research correlating to clinical human practice was discussed.
Table 1
Species Medial femoral No. of No. of Volume (mm3)
condyle
cartilage
thickness (mm)
studies animals
utilized
Total Cartilage Subchondral
Rodent 0.1 5 Mean 30 2.17 0.12 2.05
SD 15.88 2.85 0.06 2.81
Mode 30 5.3 0.18 0
Rabbit 0.3 39 Mean 18.86 53 7.15 45.86
SD 11.57 54.64 13.35 52.78
Mode 16 21.21 2.12 19.09
Canine 0.95 16 Mean 34.82 82.39 18.43 63.86
SD 46.85 197.94 17.4 181.9
Mode 8 11.94 11.94 0
Ovine 0.45 13 Mean 23.69 359.54 18.03 341.51
SD 15.74 683.35 19.97 663.79
Mode 20 n/a 12.5 0
Caprine 1.1 13 Mean 30.55 251.65 45.71 63.67
SD 20.39 448.46 35.1 78.9
Mode 50 31.1 17.49 0
Porcine 1.5 10 Mean 9.56 107.43 43.76 63.67
SD 2.35 87.87 24.05 78.9
Mode 10 183.22 34.35 0
Equine 1.75 17 Mean 9 334.73 192.67 142.06
SD 2.03 237.87 94.21 213.08
Mode 8 137.44 137.44 0
Human 2.35 n/a Mean n/a 552.25 552.25 0
Results: 113 studies relating to single site defects were reviewed and
tabulated. The mean, mode and standard deviation of the number of
animals used per study, total defect volume, cartilage volume and sub-
chondral volume is reported in table 1. The mean defect volumes ranged
from smallest in rodents at 2.2mm3 to largest in horses at 334.7mm3.
All animal models with the exception of the horse utilized defects with
greater subchondral bone volume in comparison to cartilage. Cluster
analysis included 101 studies and placed the rodent, rabbit, ovine, canine,
porcine and caprine models in group one. Group two contained ovine,
canine, porcine, caprine and equine models. Group three contained only
equine models and commonly reported human defects. These statistics
demonstrate horses to be the most comparable to humans with respect
to cartilage defect dimensions used in research, followed by the animals
in group 2. Animal models in group 1 bear more signiﬁcant limitations as
preclinical models as they do not mimic the clinical picture in the human
patient.
Conclusions: The rabbit is the most utilized animal model but its small
skeletal anatomy and cartilage morphology have signiﬁcant limitations.
The goat is a model suitable for small defect research. The horse is a
suitable model for single site defect research. Its joint anatomy by scale
and the cartilage morphology is most comparable to the clinical scenario
of single site defects in human patients. Standardization of study design
and its outcome parameters would greatly help to compare different
studies evaluating various novel therapeutic concepts. Considering the
clinical counterpart for single site defects in the human patient during
species selection and preclinical study design may help increase the
predictive value of clinical outcome. Thus it could be a major improvement
in the process of developing novel efﬁcacious therapies.
Table 2
Group Mean SD Range
1 Thickness 0.66 0.44 1.65
Diameter 4.3 1.59 7.15
Volume 12.37 12.5 57.67
2 Thickness 1.46 0.39 1.3
Diameter 10.11 1.64 7
Volume 114.31 35.49 127.94
3 Thickness 2.05 0.31 0.6
Diameter 16.79 2.85 9.98
Volume 496.15 254.5 842.25
Total Thickness 0.97 0.66 2.25
Diameter 6.82 4.64 24.13
Volume 88.02 177.83 1151.44
52 STUDY OF MOXIBUSTION STIMULATION FOR EXPERIMENTAL
ARTHRITIS MODEL
S. Kanai. Kansai University of Health Science, Osaka, JAPAN
Purpose: Recently, moxibustion have been widely from the perspective
of the effects for pain. In clinical studies, the efﬁcacy of moxibustion has
been reported for various orthopedic diseases, including shoulder pain
and low back pain. Rat adjuvant arthritis (AA) is acute periarticular prolif-
erative synovitis which is induced by single-dose intradermal injection of
tubercle bacillus to the rat posterior foot. As one of experimental arthritis
models, rat AA is used for evaluating the efﬁcacy of drugs, especially
anti-inﬂammatory drugs, at a large number of institutions. In the present
study, rats AA were left untreated for a long time to prepare chronic pain
models. In order to examine the effectiveness of moxibustion stimulation
for pain relief, we performed the study on rat AA.
Methods: Experimental methods: Sprague-Dawley (SD) rats (6 weeks
old, 160 g of body weight) were divided into 2 groups. In groups I,
Mycobacterium butyrium suspended in parafﬁn oil, was injected into the
left hind leg of 0.6mg/0.05ml to induce adjuvant arthritis (AA). These
animals were then left untreated for 24 weeks to prepare a chronic pain
model.
Measurement of locomotor activity before and after moxibustion in each
group: Before and after moxibustion stimulation, daily locomotor activity
was measured using a metabolism measuring system in groups I and II. In
the metabolism measuring system, infrared rays are spread horizontally
